publications-banner

Information about pipeline products

PublicationView

T-DXd
Breast Cancer
Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: Results from a phase Ib study
Modi S, Park H, Murthy RK, et al.
J Clin Oncol. 2020;38(17):1887-1896.
T-DXd
Breast Cancer
Trastuzumab deruxtecan in previously treated HER2-positive breast cancer
Modi S, Saura C, Yamashita T, et al.
N Engl J Med. 2020;382(7):610-621.
Edoxaban
Cardiovascular - AF
Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): A randomised, open-label, phase 3b trial
Vranckx P, Valgimigli M, Eckardt L, et al.
Lancet. 2019;394(10206):P1335-1343.
Quizartinib
Hematology
Efficacy and safety of quizartinib in Japanese patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia in an open-label, phase 2 study
Takahashi T, Usuki K, Matsue K, et al.
Int J Hematol. 2019;110(6):665-674.
Quizartinib
Hematology
Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study
Usuki K, Handa H, Choi I, et al.
Int J Hematol. 2019;110(6):654-664.
Pexidartinib
Other/Multi
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): A randomised phase 3 trial
Tap WD, Gelderblom H, Palmerini E, et al.
Lancet. 2019;394(10197):478-487.
Quizartinib
Hematology
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): A multicentre, randomised, controlled, open-label, phase 3 trial
Cortes JE, Khaled S, Martinelli G, et al.
Lancet Oncol. 2019;20(7):984-997.
T-DXd
Breast Cancer
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: A dose-expansion, phase 1 study
Tamura K, Tsurutani J, Takahashi S, et al.
Lancet Oncol. 2019;20(6):816-826.
T-DXd
Gastric Cancer
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: A dose-expansion, phase 1 study
Shitara K, Iwata H, Takahashi S, et al.
Lancet Oncol. 2019;20(6):827-836.
Edoxaban
Cardiovascular - AF
Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: The ELIMINATE-AF trial
Hohnloser SH, Camm J, Cappato R, et al.
Eur Heart J. 2019;40(36):3013-3021.
Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  

footer